Nara Organics recalled its organic baby formula sold nationwide in Target stores and online Saturday after a multistate outbreak of infant botulism, federal authorities said.<\/p>\n
Three babies between 2 and 5 months became ill in April and May in California, Pennsylvania and Washington after consuming Nara Organics Whole Milk Organic Powdered infant formula, which is also sold on Nara.com, the U.S. Food and Drug Administration said.<\/p>\n
They were hospitalized and treated with the FDA-approved treatment for infant botulism, the agency said.<\/p>\n
Infant botulism is a rare but serious illness that occurs in babies under age 1, whose gut microbiomes are immature<\/p>\n
People who have the formula are urged to stop using it immediately, the U.S. Centers for Disease Control said in a statement. The formula is manufactured in Europe but sold only in the U.S., it added.<\/p>\n
OpenAI hit with multistate probe<\/p>\n
OpenAI received a subpoena from several states as part of a probe into the safety of customers using its chatbot as it prepares to offer stock to the public for the first time.<\/p>\n
The company behind the popular ChatGPT issued a statement saying it will respond to the inquiry \u201cconstructively\u201d and that it already has measures to protect customers.<\/p>\n
The chatbot has drawn criticism for allegedly offering encouraging words to users thinking of killing themselves or engaging criminal acts. It also has come under scrutiny for how it uses health data and other personal information of its customers.<\/p>\n
\u201cAI is a new and powerful technology, and we work every day to safely bring its benefits to people in a responsible way,\u201d an emailed statement from a spokesperson said. \u201cWe take the concerns raised by state attorneys general seriously.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Nara Organics recalled its organic baby formula sold nationwide in Target stores and online Saturday after a multistate…\n","protected":false},"author":2,"featured_media":73635,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[25,309,25980,19539,157,134,40595],"class_list":["post-73634","post","type-post","status-publish","format-standard","has-post-thumbnail","category-openai","tag-artificial-intelligence","tag-business","tag-chat","tag-fda","tag-openai","tag-technology","tag-ticker"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/73634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/comments?post=73634"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/posts\/73634\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media\/73635"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/media?parent=73634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/categories?post=73634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ai\/wp-json\/wp\/v2\/tags?post=73634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}